Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HGFAC | Q04756 | 5/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 11/20 | 0.75 |
| ▸ | F2 | P00734 | 4/20 | 0.75 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.75 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.75 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | PLAU | P00749 | 1/20 | 0.67 |
| ▸ | ACR | P10323 | 8/20 | 0.66 |
| ▸ | PLG | P00747 | 1/20 | 0.65 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30117920 | 0.99 | HGFAC (0.97) | HGFACPRSS1F2PRSS2PRSS3 | |
| SCHEMBL10636579 | 0.85 | KMT2A (0.84) | HGFACPKMKMT2A | |
| SCHEMBL542043 | 0.85 | KMT2A (0.84) | HGFACPKMKMT2A | |
| SCHEMBL18434657 | 0.85 | KMT2A (0.84) | HGFACPKMKMT2A | |
| SCHEMBL4951809 | 0.85 | KMT2A (0.84) | HGFACPKMKMT2A | |
| SCHEMBL240459 | 0.82 | PLAU (1.00) | HGFACPRSS1F2PRSS2PRSS3 | |
| SCHEMBL29029504 | 0.81 | KMT2A (1.00) | HGFACPRSS1F2PRSS2PRSS3 | |
| SCHEMBL27462144 | 0.81 | HGFAC (0.67) | HGFACPRSS1F2PRSS2PRSS3 | |
| SCHEMBL12489991 | 0.81 | PKM (0.77) | HGFACPKMKMT2A | |
| SCHEMBL16375430 | 0.81 | KMT2A (0.77) | HGFACPKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240177562-A1 | Detection of Possible Problem Gambling Behaviour | Mindway Al ApS (DK) | 2024-05-30 | — | — | US | claimed |
| US-11893854-B2 | Detection of possible problem gambling behaviour | MINDWAY AI ApS (DK) | 2024-02-06 | — | — | US | claimed |
| US-20220028213-A1 | Detection of Possible Problem Gambling Behaviour | MINDWAY AI ApS (DK) | 2022-01-27 | — | — | US | claimed |
| US-20260098080-A1 | A MODIFIED PROTEIN SCAFFOLD AND USE THEREOF | EVOLVERITAS BIOTECHNOLÓGIAI KORLÁTOLT FELELOSSÉGU TÁRSASÁG (HU) | 2026-04-09 | — | — | US | disclosed |
| EP-4594347-A2 | A MODIFIED PROTEIN SCAFFOLD AND USE THEREOF | Evolveritas Biotechnologiai Korlatolt Felelossegu Tarsasag (HU) | 2025-08-06 | — | — | EP | disclosed |
| CN-119968388-A | Modified protein scaffold and uses thereof | 爱沃利塔斯生物技术有限责任公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20240228665-A1 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | OMEROS CORPORATION | 2024-07-11 | — | — | US | disclosed |
| US-20240177562-A1 | Detection of Possible Problem Gambling Behaviour | Mindway Al ApS (DK) | 2024-05-30 | — | — | US | disclosed |
| WO-2024069200-A2 | A MODIFIED PROTEIN SCAFFOLD AND USE THEREOF | EVOLVERITAS BIOTECHNOLÓGIAI KORLÁTOLT FELELŐSSÉGŰ TÁRSASÁG (HU) | 2024-04-04 | — | — | WO | disclosed |
| US-20240076408-A1 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | OMEROS CORPORATION | 2024-03-07 | — | — | US | disclosed |
| US-11893854-B2 | Detection of possible problem gambling behaviour | MINDWAY AI ApS (DK) | 2024-02-06 | — | — | US | disclosed |
| US-11884742-B2 | Methods for treating conditions associated with MASP-2 dependent complement activation | OMEROS CORPORATION (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230391889-A1 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation | OMEROS CORPORATION | 2023-12-07 | — | — | US | disclosed |
| CN-117057287-A | Sense amplifier, sensitivity enhancement method thereof, memory and electronic equipment | 成都海光微电子技术有限公司 | 2023-11-14 | — | — | CN | disclosed |
| WO-2023099927-A1 | METHOD FOR THE PREPARATION OF A RECOMBINANT TYPE II TRANSMEMBRANE PROTEASE SERINE FRAGMENT, SAID FRAGMENT, AND ITS USE | EVOLVERITAS BIOTECHNOLÓGIAI KORLÁTOLT FELELŐSSÉGŰ TÁRSASÁG (HU) | 2023-06-08 | — | — | WO | disclosed |
| US-20220028213-A1 | Detection of Possible Problem Gambling Behaviour | MINDWAY AI ApS (DK) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098080-A1 | A MODIFIED PROTEIN SCAFFOLD AND USE THEREOF | MLX, HAX1, TPX2 | HGFAC 164/4885PRSS1 1278/4885F2 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.